Skip to main content

Lupus

      RT @Yuz6Yusof: #EULAR2023 #OP0007 What are the recent trends of autoimmune disease (AID)? A database study (22m) in UK s
      1 year 5 months ago
      #EULAR2023 #OP0007 What are the recent trends of autoimmune disease (AID)? A database study (22m) in UK showed: - 1 in 10 people had AID in the last 20yrs - socioeconomic, seasonal & regional disparities cd influence pathogenesis - CTD (SLE,pSS,SSc) tended to co-occur @RheumNow https://t.co/3DDPR2K5NC
      The pharmacology treatment in systemic lupus erythematosus (SLE) is a rapidly expanding field of research that provides excitement and optimism to both the patients and the clinicians. As we have…
      RT @bella_mehta: Medication adherence in #lupus - assessed using Optum administrative database 14 yrs. 12510 pts. Median
      1 year 5 months ago
      Medication adherence in #lupus - assessed using Optum administrative database 14 yrs. 12510 pts. Median copays were less than $ 10. Black and hispanics had significantly lower odds of adherence after adjusting for several SDOH! @rheumnow #EULAR2023 abst#AB0579 https://t.co/pO5tjzTPbz
      RT @bella_mehta: Recruitment in clinical trials is tough in #lupus and #CTD. A #EULAR2023 study of 49 trials, 1909 recor
      1 year 5 months ago
      Recruitment in clinical trials is tough in #lupus and #CTD. A #EULAR2023 study of 49 trials, 1909 records- in an unselected, real world cohort of #CTD pts, upto 50% would be excluded due to classification criteria or overlapping features etc! Abst#op0013 @RheumNow https://t.co/X3YuvgSVzo
      Baricitinib in Lupus Nephritis
      RT @Yuz6Yusof: #EULAR2023 #OP0052 Could we predict renal flares in #lupus patients treated with Belimumab for non-renal
      1 year 5 months ago
      #EULAR2023 #OP0052 Could we predict renal flares in #lupus patients treated with Belimumab for non-renal purpose? Post-hoc analyses of 3 x RCTs showed predictors were: - Current/former renal involvement - high baseline proteinuria - hypoalbuminaemia - low C3 @RheumNow https://t.co/vylWCf0XNy
      RheumNow’s expanded coverage of the #EULAR2023 annual meeting is sponsored in part by Bristol Myers Squibb. All conten
      1 year 5 months ago
      RheumNow’s expanded coverage of the #EULAR2023 annual meeting is sponsored in part by Bristol Myers Squibb. All content is chosen by RheumNow and its faculty.
      RT @Yuz6Yusof: #EULAR2023 #OP0053 Baricitinib in non-renal #lupus were inconclusive. How about Renal #SLE?An RCT showed
      1 year 5 months ago
      #EULAR2023 #OP0053 Baricitinib in non-renal #lupus were inconclusive. How about Renal #SLE?An RCT showed primary endpoint (=>50% reduction in proteinuria) was met more in Bari vs Cyclo at Wks12 & 24. Intriguing but need longer-term, composite endpoint and larger size! @RheumNow https://t.co/z3YJog6gTy
      RT @Yuz6Yusof: #EULAR2023 Could we predict renal flares in #lupus patients treated with Belimumab for non-renal purpose?
      1 year 5 months ago
      #EULAR2023 Could we predict renal flares in #lupus patients treated with Belimumab for non-renal purpose? Post-hoc analyses of 3 x RCTs showed predictors were: - Current/former renal involvement - high baseline proteinuria - hypoalbuminaemia - low C3 @RheumNow https://t.co/bBtBm1olcr
      RT @synovialjoints: Nathalie Conrad, Abstr#OP0007 @RheumNow presenting on the incidence, prevalence and co-occurrence of
      1 year 5 months ago
      Nathalie Conrad, Abstr#OP0007 @RheumNow presenting on the incidence, prevalence and co-occurrence of autoimmune disease - no evidence of overall increase in conditions. Environmental and socioeconomic factors involved in the presentation of the conditions https://t.co/3jy9NoltkG